MPC-3100

• UNSPSC Description:

  MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of Hsp90 with potential antineoplastic activity[1].

• Target Antigen:

  HSP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mpc-3100.html

• Purity:

  98.3

• Solubility:

  DMSO : 5.5 mg/mL (ultrasonic;warming)

• Smiles:

  NC1=C2C(N(CCC3CCN(C([C@@H](O)C)=O)CC3)C(SC4=C(Br)C=C(OCO5)C5=C4)=N2)=NC=N1

• Molecular Weight:

  549.44

• References & Citations:

  [1]Kim SH, et al. Discovery of (2S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor. J Med Chem. 2012 Sep 13;55(17):7480-501.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  958025-66-6